Drugs /

cisplatin

Back to Drugs List
Associated Genetic Biomarkers

Overview

Generic Name(s):
cisplatin
Trade Name(s):
Blastolem, Citoplatino, Platamine, Lederplatin, Platinol-Aq Vha Plus, Platiblastin-S, Platosin, Platinex, Briplatin, Cisplatyl, Platistin, Citosin, Platinol-Aq, Platinol- Aq, Platiran, Neoplatin, Placis, Abiplatin, Metaplatin, Platinol, and Platiblastin
NCI Definition [1]:
An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.

Biomarker-Directed Therapies

Clinical Trials

View Clinical Trials for cisplatin

Cisplatin has been investigated in 263 clinical trials, of which 225 are open and 38 are closed. Of the trials investigating cisplatin, 2 are early phase 1 (2 open), 44 are phase 1 (27 open), 32 are phase 1/phase 2 (23 open), 111 are phase 2 (103 open), 12 are phase 2/phase 3 (12 open), 57 are phase 3 (55 open), 3 are phase 4 (3 open), and 2 are no phase specified (0 open).

CDKN2A Overexpression, HPV Positive, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for cisplatin clinical trials.

Non-small cell lung carcinoma, oropharyngeal squamous cell carcinoma, and head and neck squamous cell carcinoma are the most common diseases being investigated in cisplatin clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Cisplatin
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Cisplatin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating cisplatin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
Platinol, Platinol-AQ, Abiplatin, Blastolem, Briplatin, Cisplatyl, Citoplatino, pdd, diamminodichloride, platinum, platinum, diamminedichloro-, (sp-4-2)-, cis-diamminedichloro platinum (ii), 8041, cis-diammine-dichloroplatinum, cysplatyna, cis dichlorodiammineplatinum, platinol, cisplatin, cis-diamminedichloroplatinum, diaminedichloroplatinum, cisplatin [chemical/ingredient], cacp, cis-platinum ii diamine dichloride, cddp - cisplatin, cis-platinous diamine dichloride, cisplatin, cis-diamminedichloridoplatinum, diamminedichloroplatinum cis 02, cis-diamminedichloridoplatinum, cis-diamminedichloroplatinum, cpdd, cis-dichloroammine platinum (ii), platinoxan, plastistil, cis-dichlorodiammineplatinum(ii), cis-ddp, cis-platinum compound, cis platinum, peyrone's salt, cis-platinous diamine dichloride, cddp, cisplatin product, (sp-4-2)-diamminedichloroplatinum, cis-platinum ii, cismaplat, platinum diamminodichloride, cis-diamminedichloro platinum (ii), cis-platinum ii, cis-platinum, cis-diammine-dichloroplatinum, ddp, cis-diamminedichloroplatinum, Platosin, Platistin, Platiran, Platinol-AQ VHA Plus, Platinol- AQ, Platinex, Platiblastin-S, platinum, 119875, cis-platinum, 15663-27-1, cis diamminedichloroplatinum, dichlorodiammineplatinum cis 02, cisplatin (substance), (sp-4-2)-diamminedichloroplatinum, dichlorodiammineplatinum, peyrone's chloride, cisplatina, cis-platinum ii, cis-platinum, platinum, diaminedichloro-, cis- (8ci), cisplatin, cisplatinum, platinum diamminodichloride, cis-diaminedichloroplatinum, cis platinum compound, cis-diamminedichloroplatinum(ii), cis diamminedichloroplatinum, cis-ddp, cisplatin (product), platinum, diaminedichloro-, cis- (8ci), cisplatinum, cis-diamminedichloroplatinum(ii), cis-platinum ii diamine dichloride, Neoplatin, Metaplatin, Lederplatin, Citosin, Platiblastin, Platamine, Placis
Drug Categories [2]:
Alkylating agents
NCIT ID [1]:
C376
SNOMED ID [1]:
F-61AAB

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.